Prospect of rindopepimut in the treatment of glioblastoma
Elsamadicy AA, Chongsathidkiet P, Desai R, Woroniecka K, Farber SH, Fecci PE, Sampson JH. Prospect of rindopepimut in the treatment of glioblastoma. Expert Opinion On Biological Therapy 2017, 17: 507-513. PMID: 28274144, PMCID: PMC5787389, DOI: 10.1080/14712598.2017.1299705.Peer-Reviewed Original ResearchConceptsKeyhole limpet hemocyaninClinical efficacyClinical trialsEpidermal growth factor receptor variant IIIPhase III clinical trialsPhase II clinical trialPrimary malignant neoplasmsTreatment of GBMSub-group analysisTumor-specific epitopesTreatment of glioblastomaTumor-specific activityPrimary endpointClinical benefitMalignant neoplasmsPeptide vaccineInhibition of apoptosisSignificant efficacyGBM therapyRindopepimutAmino acid peptideLimpet hemocyaninVariant IIIGBM cellsEGFRvIII mutation